JP2005504787A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005504787A5 JP2005504787A5 JP2003526373A JP2003526373A JP2005504787A5 JP 2005504787 A5 JP2005504787 A5 JP 2005504787A5 JP 2003526373 A JP2003526373 A JP 2003526373A JP 2003526373 A JP2003526373 A JP 2003526373A JP 2005504787 A5 JP2005504787 A5 JP 2005504787A5
- Authority
- JP
- Japan
- Prior art keywords
- suspension
- peptide
- hydrophobic peptide
- aqueous suspension
- gnrh
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 22
- 239000000725 suspension Substances 0.000 claims 20
- 239000007900 aqueous suspension Substances 0.000 claims 15
- 230000002209 hydrophobic effect Effects 0.000 claims 15
- 239000002474 gonadorelin antagonist Substances 0.000 claims 12
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 claims 12
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 7
- 239000007951 isotonicity adjuster Substances 0.000 claims 7
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 6
- 150000002500 ions Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- 229930195725 Mannitol Natural products 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 4
- 239000012736 aqueous medium Substances 0.000 claims 4
- 239000012530 fluid Substances 0.000 claims 4
- 239000012931 lyophilized formulation Substances 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- 239000000594 mannitol Substances 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 108010023617 abarelix Proteins 0.000 claims 3
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims 3
- 229960002184 abarelix Drugs 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 229940127233 azaline B Drugs 0.000 claims 3
- 108700008462 cetrorelix Proteins 0.000 claims 3
- 229960003230 cetrorelix Drugs 0.000 claims 3
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 108700032141 ganirelix Proteins 0.000 claims 3
- 229960003794 ganirelix Drugs 0.000 claims 3
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims 2
- 108010070670 antarelix Proteins 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 238000011065 in-situ storage Methods 0.000 claims 2
- 108010083551 iturelix Proteins 0.000 claims 2
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000013081 microcrystal Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 229950011372 teverelix Drugs 0.000 claims 2
- -1 antid Chemical compound 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000012929 tonicity agent Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31761601P | 2001-09-06 | 2001-09-06 | |
| PCT/EP2002/009537 WO2003022243A2 (en) | 2001-09-06 | 2002-08-27 | Sustained release of microcrystalline peptide suspensions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010016716A Division JP5757686B2 (ja) | 2001-09-06 | 2010-01-28 | 微晶質ペプチド懸濁液の徐放性 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005504787A JP2005504787A (ja) | 2005-02-17 |
| JP2005504787A5 true JP2005504787A5 (enExample) | 2005-12-22 |
Family
ID=23234486
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003526373A Pending JP2005504787A (ja) | 2001-09-06 | 2002-08-27 | 微晶質ペプチド懸濁液の徐放性 |
| JP2010016716A Expired - Lifetime JP5757686B2 (ja) | 2001-09-06 | 2010-01-28 | 微晶質ペプチド懸濁液の徐放性 |
| JP2013122235A Pending JP2013177449A (ja) | 2001-09-06 | 2013-06-10 | 疎水性ペプチドの徐放性処方物の製造法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010016716A Expired - Lifetime JP5757686B2 (ja) | 2001-09-06 | 2010-01-28 | 微晶質ペプチド懸濁液の徐放性 |
| JP2013122235A Pending JP2013177449A (ja) | 2001-09-06 | 2013-06-10 | 疎水性ペプチドの徐放性処方物の製造法 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US7098305B2 (enExample) |
| EP (2) | EP2198888B1 (enExample) |
| JP (3) | JP2005504787A (enExample) |
| KR (2) | KR20070107161A (enExample) |
| CN (1) | CN100386116C (enExample) |
| AR (1) | AR042592A1 (enExample) |
| AT (1) | ATE463258T1 (enExample) |
| AU (1) | AU2002337025B2 (enExample) |
| BR (1) | BR0212333A (enExample) |
| CA (1) | CA2459309C (enExample) |
| CY (1) | CY1118642T1 (enExample) |
| DE (1) | DE60235896D1 (enExample) |
| DK (1) | DK2198888T3 (enExample) |
| ES (2) | ES2362505T3 (enExample) |
| HU (1) | HUP0402099A2 (enExample) |
| IL (1) | IL160443A0 (enExample) |
| MX (1) | MXPA04002185A (enExample) |
| NO (1) | NO20040938L (enExample) |
| NZ (1) | NZ531734A (enExample) |
| PL (1) | PL368056A1 (enExample) |
| PT (1) | PT2198888T (enExample) |
| RU (1) | RU2311195C2 (enExample) |
| TW (1) | TWI249409B (enExample) |
| UA (1) | UA79435C2 (enExample) |
| WO (1) | WO2003022243A2 (enExample) |
| ZA (1) | ZA200401390B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US7358330B2 (en) * | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
| US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| AR044852A1 (es) * | 2003-06-24 | 2005-10-05 | Novartis Ag | Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina |
| GB0320806D0 (en) | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Therapeutic treatment |
| KR101438983B1 (ko) | 2003-11-06 | 2014-09-05 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
| GB0428151D0 (en) * | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
| EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| GB0511269D0 (en) * | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
| JP5242415B2 (ja) * | 2006-01-18 | 2013-07-24 | フォアシーエイサー ファーマシューティカルズ インコーポレイテッド | 高い安定性を持つ薬理組成物 |
| BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| WO2008071984A1 (en) * | 2006-12-13 | 2008-06-19 | Ardana Bioscience Limited | Administration of the gonadotropin-releasing hormone antagonist teverelix |
| JP5469600B2 (ja) | 2007-07-16 | 2014-04-16 | ジェネンテック, インコーポレイテッド | 抗CD79b抗体及びイムノコンジュゲートとその使用方法 |
| EP2176295B1 (en) | 2007-07-16 | 2014-11-19 | Genentech, Inc. | Humanized anti-cd79b antibodies and immunoconjugates and methods of use |
| ES2643239T3 (es) | 2008-01-31 | 2017-11-21 | Genentech, Inc. | Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso |
| TW200950799A (en) * | 2008-05-07 | 2009-12-16 | Merrion Res Iii Ltd | Compositions of GnRH related compounds and processes of preparation |
| TWI480286B (zh) * | 2009-02-25 | 2015-04-11 | Merrion Res Iii Ltd | 雙膦酸鹽類組合物及藥物遞送 |
| EP2424503B1 (en) * | 2009-05-01 | 2017-07-05 | Ferring BV | Composition for the treatment of prostate cancer |
| SG182548A1 (en) | 2010-01-13 | 2012-08-30 | Ipsen Pharma Sas | Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| WO2011120033A1 (en) * | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| US8927687B2 (en) | 2010-07-09 | 2015-01-06 | Amylin Pharmaceuticals, Llc | Microcrystalline Y receptor agonists |
| CN103476419A (zh) | 2011-01-07 | 2013-12-25 | 梅里翁第三研究有限公司 | 口服投药的含铁药物组合物 |
| EP2922818B1 (en) | 2012-11-24 | 2018-09-05 | Hangzhou Dac Biotech Co., Ltd | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| EP2823808A1 (en) | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
| EP2832361A1 (en) * | 2013-07-29 | 2015-02-04 | Ipsen Pharma S.A.S. | Aqueous sustained release compositions of LHRH analogs |
| CN104844694A (zh) * | 2014-02-17 | 2015-08-19 | 深圳翰宇药业股份有限公司 | 一种醋酸加尼瑞克的制备方法 |
| WO2015127685A1 (en) | 2014-02-28 | 2015-09-03 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
| EP3262071B8 (en) | 2014-09-23 | 2022-05-18 | F. Hoffmann-La Roche AG | Method of using anti-cd79b immunoconjugates |
| US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
| CN108026123B (zh) | 2015-06-15 | 2021-02-05 | 杭州多禧生物科技有限公司 | 用于偶联的亲水链接体 |
| CA2991973C (en) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Bridge linkers for conjugation of a cell-binding molecule |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| KR102345175B1 (ko) | 2016-11-14 | 2021-12-31 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
| KR20190112029A (ko) * | 2017-01-30 | 2019-10-02 | 안테브 리미티드 | 적어도 하나의 gnrh 길항제를 포함하는 조성물 |
| DE212018000251U1 (de) | 2017-06-30 | 2020-05-12 | Antev Limited | Zusammensetzung zur Behandlung akuter Harnverhaltung |
| EP3560555A1 (en) | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
| KR20210016365A (ko) * | 2018-05-28 | 2021-02-15 | 장인 우선 파마슈티컬 컴퍼니 리미티드 | 새로운 약제학적 용도 |
| EP3590526A1 (en) * | 2018-07-05 | 2020-01-08 | Antev Limited | A lyophilization process and a teverelix-tfa lyophilizate obtained thereby |
| EP3590525A1 (en) * | 2018-07-05 | 2020-01-08 | Antev Limited | Teverelix-tfa composition |
| EP3590524B1 (en) * | 2018-07-05 | 2020-11-04 | Antev Limited | A method of reconstituting a teverelix-tfa composition |
| AU2021362997A1 (en) | 2021-11-03 | 2024-05-16 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2668866A (en) * | 1951-08-14 | 1954-02-09 | Shell Dev | Isomerization of paraffin wax |
| GB1245187A (en) | 1969-02-14 | 1971-09-08 | Continental Can Co | Hot melt adhesive composition |
| JPS5242506A (en) | 1975-10-02 | 1977-04-02 | Toa Nenryo Kogyo Kk | Hydrotreating process of petroleum wax |
| JPS5335705A (en) * | 1976-09-14 | 1978-04-03 | Toa Nenryo Kogyo Kk | Hydrogenation and purification of petroleum wax |
| US4186078A (en) * | 1977-09-12 | 1980-01-29 | Toa Nenryo Kogyo Kabushiki Kaisha | Catalyst and process for hydrofining petroleum wax |
| US4239546A (en) * | 1978-07-21 | 1980-12-16 | Petrolite Corporation | Hydrocarbon polymers to improve the hardness of waxes |
| US4256737A (en) | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
| US4266737A (en) * | 1979-11-05 | 1981-05-12 | Arrow Converting Equipment, Inc. | Air differential mandrel and method of differentially winding and rewinding tapes |
| US4415649A (en) * | 1981-02-25 | 1983-11-15 | E. I. Du Pont De Nemours & Co. | Flexographic printing plates containing blended adhesives |
| US4839422A (en) * | 1987-12-23 | 1989-06-13 | Exxon Chemical Patents Inc. | Ternary adhesive compositions |
| WO1989007450A1 (en) | 1988-02-10 | 1989-08-24 | Abbott Laboratories | Lhrh analogs |
| US5110904A (en) * | 1989-08-07 | 1992-05-05 | Abbott Laboratories | Lhrh analogs |
| JP2672677B2 (ja) | 1989-02-09 | 1997-11-05 | タツプ・フアーマシユーテイカルズ・インコーポレイテツド | Lhrh同族体 |
| DE593491T1 (de) * | 1991-04-25 | 1994-11-17 | Romano S.-Cergue Deghenghi | LHRH-Antagonisten. |
| KR100225983B1 (ko) * | 1992-10-26 | 1999-10-15 | 클라우스-디터 홈메리히, 디트리히 빌헬름 샤흐트 | 마이크로캡슐의 제조 방법 |
| WO1994013313A1 (en) | 1992-12-04 | 1994-06-23 | Abbott Laboratories | 6-position modified decapeptide lhrh antagonists |
| WO1994014841A1 (en) | 1992-12-18 | 1994-07-07 | Abbott Laboratories | Lhrh antagonists having modified aminoacyl residues at postions 5 and 6 |
| CA2178592C (en) | 1993-12-09 | 2009-07-28 | Jurgen Engel | Long-acting injection suspensions and a process for their preparation |
| DE4342092B4 (de) * | 1993-12-09 | 2007-01-11 | Zentaris Gmbh | Langwirkende Injektionssuspension und Verfahren zur Herstellung |
| JP3101695B2 (ja) | 1996-07-24 | 2000-10-23 | 日本航空電子工業株式会社 | 軟x線光学素子用多層膜 |
| US5968895A (en) | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| DE19813849A1 (de) * | 1998-03-27 | 1999-09-30 | Degussa | Verfahren zur einstufigen Umsalzung und Aufreinigung von Oligopeptiden |
| CO5160256A1 (es) | 1999-02-08 | 2002-05-30 | Zentaris Ag | Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion |
| DE10040700A1 (de) * | 2000-08-17 | 2002-02-28 | Asta Medica Ag | Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung |
| US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| JP4505750B2 (ja) | 2006-01-27 | 2010-07-21 | 東海ゴム工業株式会社 | 制振装置 |
-
2002
- 2002-02-19 US US10/080,130 patent/US7098305B2/en not_active Expired - Lifetime
- 2002-08-27 HU HU0402099A patent/HUP0402099A2/hu unknown
- 2002-08-27 DK DK10003046.9T patent/DK2198888T3/en active
- 2002-08-27 EP EP10003046.9A patent/EP2198888B1/en not_active Expired - Lifetime
- 2002-08-27 AT AT02772214T patent/ATE463258T1/de active
- 2002-08-27 IL IL16044302A patent/IL160443A0/xx unknown
- 2002-08-27 JP JP2003526373A patent/JP2005504787A/ja active Pending
- 2002-08-27 BR BR0212333-9A patent/BR0212333A/pt not_active IP Right Cessation
- 2002-08-27 CA CA2459309A patent/CA2459309C/en not_active Expired - Lifetime
- 2002-08-27 KR KR1020077021972A patent/KR20070107161A/ko not_active Ceased
- 2002-08-27 RU RU2004110615/15A patent/RU2311195C2/ru not_active IP Right Cessation
- 2002-08-27 PT PT100030469T patent/PT2198888T/pt unknown
- 2002-08-27 NZ NZ531734A patent/NZ531734A/en not_active IP Right Cessation
- 2002-08-27 ES ES02772214T patent/ES2362505T3/es not_active Expired - Lifetime
- 2002-08-27 KR KR1020047003371A patent/KR100818904B1/ko not_active Expired - Lifetime
- 2002-08-27 UA UA2004031905A patent/UA79435C2/uk unknown
- 2002-08-27 WO PCT/EP2002/009537 patent/WO2003022243A2/en not_active Ceased
- 2002-08-27 PL PL02368056A patent/PL368056A1/xx unknown
- 2002-08-27 DE DE60235896T patent/DE60235896D1/de not_active Expired - Lifetime
- 2002-08-27 MX MXPA04002185A patent/MXPA04002185A/es not_active Application Discontinuation
- 2002-08-27 ES ES10003046.9T patent/ES2618777T3/es not_active Expired - Lifetime
- 2002-08-27 AU AU2002337025A patent/AU2002337025B2/en not_active Ceased
- 2002-08-27 EP EP02772214A patent/EP1423150B1/en not_active Expired - Lifetime
- 2002-08-27 CN CNB028173775A patent/CN100386116C/zh not_active Expired - Lifetime
- 2002-08-29 TW TW091119713A patent/TWI249409B/zh not_active IP Right Cessation
- 2002-09-05 AR ARP020103358A patent/AR042592A1/es unknown
-
2004
- 2004-02-20 ZA ZA200401390A patent/ZA200401390B/en unknown
- 2004-03-04 NO NO20040938A patent/NO20040938L/no not_active Application Discontinuation
-
2006
- 2006-06-12 US US11/450,292 patent/US20060229238A1/en not_active Abandoned
- 2006-06-12 US US11/450,293 patent/US20060228385A1/en not_active Abandoned
-
2010
- 2010-01-28 JP JP2010016716A patent/JP5757686B2/ja not_active Expired - Lifetime
- 2010-06-07 US US12/795,246 patent/US20100239683A1/en not_active Abandoned
-
2011
- 2011-09-01 US US13/224,105 patent/US8415300B2/en not_active Expired - Lifetime
-
2013
- 2013-06-10 JP JP2013122235A patent/JP2013177449A/ja active Pending
-
2017
- 2017-02-02 CY CY20171100156T patent/CY1118642T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005504787A5 (enExample) | ||
| RU2004110615A (ru) | Способ предупреждения формирования геля гидрофобного пептида, композиция гидрофобного пептида (варианты) и способ ее получения (варианты) | |
| AU2002337025A1 (en) | Sustained release of microcrystalline peptide suspensions | |
| CN104394878A (zh) | 用于治疗周围血管疾病的组合物和方法 | |
| EP0938496A1 (en) | Heptapeptide oxytocin analogues | |
| CA2412759A1 (en) | Injectable solution of an lhrh antagonist | |
| RU2004119821A (ru) | Водный инъекционный раствор антагониста lhrh и способ его получения | |
| PT95953A (pt) | Processo para a preparacao de derivados peptidicos e de composicoes farmaceuticas que os contem | |
| RU2239457C2 (ru) | Фармацевтическая композиция пролонгированного действия и способ ее получения | |
| RU2001125033A (ru) | Фармацевтическая композиция и способ ее получения | |
| RU2003107560A (ru) | Соль пептида (варианты), способ ее получения и применение, фармацевтическая композиция и способ ее получения | |
| JP2003252751A5 (enExample) | ||
| Janecka et al. | Superiority of an antagonist of the luteinizing hormone releasing hormone with emphasis on arginine in position 8, named Argtide | |
| FI933629L (fi) | Antagonistpeptider till hormon som frigoer luteiniserande hormon (lhrh) |